Evidence map›Paper›PMID 39505607›Full record

ArticleJournal of geriatric oncology2025

Predictive ability of the Cancer and Aging Research Group chemotherapy toxicity calculator in hematologic malignancy.

Ashley E Rosko, Ying Huang, Sarah A Wall, Alice Mims, Jennifer Woyach, Carolyn Presley, Nicole O Williams, Erin Stevens, Claire J Han, Diane Von Ah and 4 more

Abstract read
In one paragraph

Article in Journal of geriatric oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Predictive value of the Cancer and Aging Research Group Score for chemotherapy toxicities in older adults with cancer: a systematic review and meta-analysis.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026
    Pooled it
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Ashley E RoskoDivision of Hematology, The Ohio State University, Columbus, OH, United States of America. Electronic address: Ashley.Rosko@osumc.edu.
Ying HuangDivision of Hematology, The Ohio State University, Columbus, OH, United States of America.
Sarah A WallDivision of Hematology, The Ohio State University, Columbus, OH, United States of America.
Alice MimsDivision of Hematology, The Ohio State University, Columbus, OH, United States of America.
Jennifer WoyachDivision of Hematology, The Ohio State University, Columbus, OH, United States of America.
Carolyn PresleyDivision of Medical Oncology, The Ohio State University, Columbus, OH, United States of America.
Nicole O WilliamsDivision of Medical Oncology, The Ohio State University, Columbus, OH, United States of America.
Erin StevensDivision of Palliative Care, The Ohio State University, Columbus, OH, United States of America.
Claire J HanCollege of Nursing, Center for Healthy Aging, Self-Management and Complex Care, The Ohio State University, Columbus, OH, United States of America.
Diane Von AhCollege of Nursing, Center for Healthy Aging, Self-Management and Complex Care, The Ohio State University, Columbus, OH, United States of America.
Nowshin IslamDivision of Hematology, The Ohio State University, Columbus, OH, United States of America.
Jessica L Krok-SchoenSchool of Health and Rehabilitation Sciences, College of Medicine The Ohio State University, Columbus, OH, United States of America.
Christin E BurdDepartments of Molecular Genetics, Cancer Biology and Genetics, The Ohio State University, Columbus, OH, United States of America.
Michelle J NaughtonDepartment of Internal Medicine, The Ohio State University, Columbus, OH, United States of America.

Funding

Translational Therapeutics Research Program (TT)P30CA016058 · NCI · OHIO STATE UNIVERSITY · PI Daniel G. Stover · 1985 to 2026
$132.3M
NCI NIH HHS L30 CA188836NCI NIH HHS P30 CA016058
6 · The paper itself

Abstract

introductionChemotherapy toxicity tools are rarely studied in patients with hematologic malignancy (HM). The primary aim of this pilot study was to determine the predictive ability of the Cancer and Aging Research Group (CARG) chemo-toxicity calculator in estimating grade 3-5 toxicity in patients with HM. MATERIALS AND

methodsPatients 60 years and older with HM were prospectively evaluated using the CARG chemo-toxicity calculator. Discrimination and calibration were checked by applying the published model in our data. Additionally, a full geriatric assessment (GA), the Short Physical Performance Battery (SPPB), and health related quality of life (HRQoL) were captured longitudinally at the start of treatment and at end of study. Secondary aims explored the association of GA metrics with chemo-related toxicities and survival.

resultsOne hundred forty-five patients were approached, 118 patients consented, and 97 patients were evaluable. Most patients were newly diagnosed (n = 91). The median CARG score was 9 (range 4-18). The CARG score was not validated in our cohort of older patients with HM, with area under the receiver operation characteristic curve being 0.53 (95 % CI: 0.41-0.65). In multivariable analysis, after controlling for disease type, risk factors associated with grade 3-5 toxicity included living alone (hazard ratio [HR] 4.24, 95 %CI: 2.07-8.68, p < 0.001), increase in body mass index (HR 1.06, 95 %CI: 1.01-1.12, p = 0.03) and a higher social activities score (HR 1.27, 95 %CI: 1.06-1.51, p = 0.01). In multivariable analysis of overall survival, the only prognostic factor was an objective marker of physical function (SPPB score HR = 0.85, 95 %CI:0.78-0.93, p < 0.001). DISCUSSION: The CARG chemo-toxicity calculator was not predictive of grade 3-5 toxicity in patients with hematologic malignancy. The SPPB was associated with overall survival in multivariable analysis, suggesting future use as an objective biomarker in HM. We also report a comprehensive trajectory of function, QoL, psychosocial well-being, and cognition among older adults with HM. The predictive accuracy of the CARG chemo-toxicity calculator may be affected by the diverse range of HM treatment options that are not traditional chemotherapy.

Indexed as

Geriatric AssessmentHematologic NeoplasmsQuality of LifeAgedAged, 80 and overAntineoplastic AgentsFemaleHumansMaleMiddle AgedPhysical Functional PerformancePilot ProjectsPredictive Value of TestsProspective StudiesAntineoplastic AgentsChemotherapy toxicityFrailtyGeriatric assessmentHematologic malignancy

Identifiers

PMID39505607
PMCPMC12147674

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.